A Phase 4 interventional study of Silodosin and Tamsolusin in BPH (Benign Prostatic Hyperplasia), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Completed at 6 sites in China. Open to male participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.
Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 11 in phase 4, and was the 15th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Mohsen Pourazizi
Ages 50+ · Men only
Mohsen Pourazizi
Ages 50+ · Men only
Ain Shams University · Sites in Egypt
Ages 50+ · Men only
By country, each count listing its studies:
silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 60 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2022.
This study's enrollment of 110 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 141 across the 19 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 19 have an industry lead sponsor. The 10 most frequent:
Shanghai Huilun Pharmaceutical Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Shanghai Huilun Pharmaceutical Co., Ltd. has 2 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
3 of the studies testing silodosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing silodosin in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if Qianweitai (QWT, silodosin capsule) works to treat BPH/LUTS in male adults. It will also learn the safety about QWT. The main questions it aims to answer are:
Participants will:
This trial is designed as two stages: screening period, treatment and follow-up period.
Screening period (days -28 to 0): After signing the informed consent form, the subjects entered into the screening period, and made a 24-hour urination diary and screening examination.
Treatment and Follow-up period: eligible patients were randomly assigned to 2 groups according to 1: 1 and received Tamsulosin or Silodosin or for 12 weeks. During the treatment period, the subjects' diaries were recorded according to the requirements of the scheme, and they were followed up at 1 week (7±2 days), 2 weeks (14±3), 4 weeks (28±5 days), 8 weeks (56±7 days) and 12 weeks (84±10 days). During the visit, relevant scale scores and laboratory examinations were performed, and the occurrence of adverse events during the follow-up was recorded to evaluate the safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients orally take Qianweitai (silodosin capsule), 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner).
Drug: Silodosin
Patients orally take tamsulosin hydrochloride capsules (1 tablet each time, once daily).
Drug: Tamsolusin
Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.
Also known as: Qianweitai
Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Also known as: Harnal
International Prostate Symptom Score(IPSS)
Changes of IPSS scores at the 12th week of treatment compared with baseline scores.
Time frame: week 12
International Prostate Symptom Score(IPSS) total score
Changes of IPSS scores at 1, 2, 4 and 8 weeks after treatment compared with baseline
Time frame: 1, 2, 4 and 8 weeks
IPSS storage subscore
Changes of IPSS storage subscore at 1, 2, 4 and 8 weeks after treatment compared with baseline
Time frame: 1, 2, 4 and 8 weeks
IPSS voiding subscore
Changes of IPSS voiding subscore at 1, 2, 4 and 8 weeks after treatment compared with baseline
Time frame: 1, 2, 4 and 8 weeks
IPSS total score severity
Proportion of patients with IPSS total score severity decreased by at least one grade at 12 weeks. The scores of the scale were divided into three grades: mild (0-7), moderate (8-19) and severe (20-35).
Time frame: week 12
Quality of life (QoL) score
Changes in scores at 4, 8 and 12 weeks of treatment compared with baseline.The scores of the scale ranged from 0 to 6. The higher the score, the more severe the symptoms are.
Time frame: 4, 8 and 12 weeks
Maximum urinary flow rate (Qmax)
The change of Qmax at the 12th week of treatment compared with baseline.
Time frame: week 12
Residual urine volume (PVR)
The change of PVR at the 12th week of treatment compared with baseline.
Time frame: week 12
Prostate specific antigen (PSA)
The change of PSA at the 12th week of treatment compared with baseline.
Time frame: week 12
Prostate volume (PV)
Changes of PV at 12 the 12th week of treatment compared with baseline.
Time frame: week 12
Responder rate
Responder rate is defined as the proportion of patients whose IPSS total score decreased by ≥ 25% and Qmax increased by ≥ 30% compared with baseline value after treatment.
Time frame: week 12
Proportion of patients with BPH clinical progression
Clinical progress is defined as the first occurrence of one of the following two conditions during the trial: 1. Acute urinary retention (AUR); 2. Clinical diagnosis requires surgical treatment of BPH.
Time frame: week 12
Ran from Jul 2022 to primary completion in Jul 2024, 23 months.
Of 28 phase 4 interventional studies under Prostatic Hyperplasia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin
Shanghai Huilun Pharmaceutical Co., Ltd.